A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 366 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... October 20, 2020 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to... March 14, 2025 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... May 4, 2021 Load more HOT NEWS Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... A ‘sponge on a string’ test to detect oesophageal cancer earlier
